Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vector Science and TherapeuticsTSXV:PAIN -4.31%15 Return-on-Tangible-Asset is -512.05% as of May. 2026. GuruFocus rates TSXV:PAIN with a GF Score™ of 15/100. Among 852 Medical Devices & Instruments companies, Vector Science and Therapeutics ranks worse than 94.6% on this metric.
The historical rank and industry rank for Vector Science and Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
TSXV:PAIN'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -165.44 Med: -60.22 Max: -60.22
Current: -165.44
During the past 2 years, Vector Science and Therapeutics's highest Return-on-Tangible-Asset was -60.22%. The lowest was -165.44%. And the median was -60.22%.
TSXV:PAIN's Return-on-Tangible-Asset is ranked worse than 94.6% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.925
vs TSXV:PAIN: -165.44
Vector Science and Therapeutics (TSXV:PAIN) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Vector Science and Therapeutics Return-on-Tangible-Asset Related Terms
Vector Science and Therapeutics Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vector Science and Therapeutics Return-on-Tangible-Asset Chart
TSXV:PAIN vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Vector Science and Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vector Science and Therapeutics Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vector Science and Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Vector Science and Therapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (May. 2026) net income data.
What does a Return-on-Tangible-Asset of -512.05% mean?
Vector Science and Therapeutics (TSXV:PAIN) has a Return-on-Tangible-Asset of -512.05% as of May. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vector Science and Therapeutics and its competitors. According to the industry distribution chart, Vector Science and Therapeutics ranks #806 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 94.6%.
Is Vector Science and Therapeutics' Return-on-Tangible-Asset too high?
Vector Science and Therapeutics' current Return-on-Tangible-Asset is -512.05%. Based on the distribution chart, Vector Science and Therapeutics ranks #806 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vector Science and Therapeutics has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vector Science and Therapeutics ranks #806 out of 852 companies for Return-on-Tangible-Asset. This places Vector Science and Therapeutics in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.93, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vector Science and Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vector Science and Therapeutics's current Return-on-Tangible-Asset is -512.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current Return-on-Tangible-Asset of -512.05%. The current Return-on-Tangible-Asset is -512.05%. Vector Science and Therapeutics' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current Return-on-Tangible-Asset is -512.05% as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
15GF Score
Get the complete analysis for TSXV:PAIN
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PAIN has been successfully added to your 
